Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such ...

And that's why Merck could credibly become the next big weight-loss stock. Before you rush to go buy shares of Merck, ...

News of a fresh licensing deal by a well-capitalized rival sent Viking Therapeutics ( VKTX 0.17%) stock into something of a tailspin this week. According to data compiled by S&P Global Market ...

The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...

Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) ...

Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a ...

Merck has entered into a global licensing agreement with Chinese biopharmaceutical company Hansoh Pharma to develop an oral small molecule GLP-1 receptor agonist, HS-10535.

To foray into the lucrative obesity market, Merck MRK announced that it is in-licensing global rights to an investigational ...

Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my ...

Merck has entered a $2 billion licensing deal with China's Hansoh Pharma for an oral weight-loss drug, positioning itself ...

By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals' dominance in the GLP-1 ...

Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its ...